©2022 Stanford Medicine
Mixed Chimera Allogeneic Transplantation From Matched Unrelated Donors For The Treatment Of Multiple Myeloma
Not Recruiting
Trial ID: NCT00185653
Purpose
The purpose of the study is to determine the toxicity and feasibility of non-myeloablative
allogeneic hematopoietic cell transplants for multiple myeloma from unrelated donors.
Official Title
Mixed Chimera Allogeneic Transplantation From Matched Unrelated Donors for the Treatment of Multiple Myeloma
Stanford Investigator(s)
Robert Lowsky
Professor of Medicine (Blood and Marrow Transplantation and Cellular Therapy)
Laura Johnston
Professor of Medicine (Blood and Marrow Transplantation and Cellular Therapy)
Robert Negrin
Professor of Medicine (Blood and Marrow Transplantation and Cellular Therapy)
Sally Arai
Associate Professor of Medicine (Blood and Marrow Transplantation and Cellular Therapy)
Judith Shizuru
Professor of Medicine (Blood and Marrow Transplantation and Cellular Therapy) and of Pediatrics (Stem Cell Transplantation)
Eligibility
Inclusion Criteria:a) Multiple myeloma which is responsive to therapy. Eligible patients
may have early or relapsed disease. Patients must have Stage II-III disease or have
progression after initial treatment of Stage I disease. Patients who have relapsed
following autologous transplantation may be eligible for this protocol.
b) Age <= 60 years. c) No prior therapy which would preclude the use of low-dose total body
irradiation.
d) Patients must have their pathology reviewed and the diagnosis confirmed at Stanford
University Medical Center. Patients with smoldering multiple myeloma, monoclonal gammopathy
of unknown significance, or amyloidosis will be excluded from this study.
e) Patients must have a Karnofsky performance status > 70%. f) DLCO >= 60% predicted. g)
ALT and AST must be < 2X normal. Total bilirubin less than 2 mg/dl. h) Serum creatinine <
2.0 or 24-hour creatinine clearance >= 50 ml/min. i) Patients must be HIV negative. j)
Pregnant or lactating women will not be eligible to participate. k) Patients must provide
signed, informed consent. Exclusion Criteria:a) Severe psychological or medical illness b)
Patients who have undergone prior allogeneic hematopoietic cell transplantation will not be
eligible for this study.
c) Patients who have an HLA-identical sibling donor will be excluded
Intervention(s):
procedure: Autologous followed by non-myeloablative allogeneic transplantation
Not Recruiting
Contact Information
Stanford University
School of Medicine
300 Pasteur Drive
Stanford,
CA
94305
BMT Referrals
6507230822